TFS HealthScience Extends Oncomatryx Collaboration for OMTX705 Pancreatic Cancer Trial

TFS HealthScience, a prominent Contract Research Organization (CRO) based in Lund, Sweden, is intensifying its partnership with Oncomatryx, a biopharmaceutical company specializing in the development of innovative antibody-drug conjugates (ADCs). This expanded collaboration will focus on supporting a newly launched Phase Ib clinical trial aimed at evaluating OMTX705. This drug is an anti-fibroblast activation protein antibody-drug conjugate (FAP-ADC) that targets the tumor microenvironment in patients suffering from advanced or metastatic pancreatic adenocarcinoma. The trial is set to take place at multiple sites in Spain and the United States.

Pancreatic cancer, as per the World Cancer Research Foundation, is among the most lethal forms of cancer worldwide, with over 510,000 new cases and more than 466,000 deaths annually. Despite progress in oncology, treatment options for advanced or metastatic pancreatic cancer are limited, and the five-year survival rate remains under 10%. This grim statistic highlights the urgent necessity for new and effective treatment options.

The Phase Ib study follows an earlier collaboration between TFS and Oncomatryx during a Phase I trial. In this trial, OMTX705 was evaluated both as a standalone treatment and in conjunction with pembrolizumab for patients with advanced solid tumors. The encouraging results from the initial study set the stage for this subsequent phase of development, showcasing the consistent performance and deep expertise in oncology that Oncomatryx values in its ongoing partnership with TFS.

Kris O'Brien, Vice President and Head of Oncology & Rare Diseases at TFS, stated, "Our ongoing collaboration with Oncomatryx signifies a mutual commitment to fast-tracking the development of groundbreaking therapies for complex cancers such as pancreatic adenocarcinoma. TFS's profound therapeutic insights and operational flexibility are crucial in advancing promising scientific projects."

Laureano Simón, CEO of Oncomatryx, expressed enthusiasm about the upcoming phase in the clinical development of OMTX705. He emphasized that TFS has proven to be a reliable and expert partner, essential in progressing their science to patients who are in urgent need of new treatment options.

TFS boasts over two decades of experience in oncology research, supporting clinical trials for solid tumors, hematological malignancies, and rare cancers. With a focus on agility, scientific rigor, and a global presence, TFS has adeptly managed numerous early and late-phase oncology programs from concept to clinical trials. Through sustained partnerships, including the renewed collaboration with Oncomatryx, TFS continues to provide tailored clinical solutions, advancing scientific endeavors with the overarching aim of enhancing patient lives globally.

The OMTX705 program is gaining traction, bolstered by robust financial support following a €25 million fundraising round completed at the end of 2024. With Phase I clinical data anticipated to be showcased at major oncology conferences throughout 2025, the program is drawing increased interest as a promising new treatment for challenging tumors like pancreatic adenocarcinoma.

TFS HealthScience is a comprehensive global CRO that collaborates with biotechnology and pharmaceutical companies to foster development of innovative treatments and improve patient outcomes. Operating across 40 countries, TFS and its strategic partners offer customized resourcing solutions and clinical development services in specialized therapeutic fields, including oncology. TFS is committed to empowering its partners while enriching lives through flexible solutions that combine global reach with the agility of a mid-sized CRO.

Oncomatryx has developed a unique Antibody-Drug Conjugates platform targeting Cancer-Associated Fibroblasts within the microenvironment of metastatic solid tumors. Their pioneering efforts in ADCs against immunosuppressive cancer-associated fibroblasts are developed in collaboration with esteemed universities, hospitals, and research centers across the USA and Europe.